USFDA issues 11 observations after inspection of Cadila Healthcare's St Louis facilities

Image
Press Trust of India New Delhi
Last Updated : Jun 03 2019 | 4:45 PM IST

Drug firm Cadila Healthcare Monday said the US health regulator has issued a total of 11 observations after inspection of its manufacturing facilities at St Louis in the US.

The United States Food and Drug Administration (USFDA) inspected the manufacturing facilities of Nesher Pharmaceuticals (USA) LLC located at St Louis, Missouri, USA from May 13 to May 31, 2019, Cadila Healthcare said in a filing to BSE.

Nesher Pharmaceuticals LLC is a 100 per cent subsidiary of Zydus Pharmaceuticals USA, it added.

"The inspection concluded with 3 observations at one facility and 8 observations at the other facility of Nesher Pharmaceuticals with a recommendation for Voluntary Action Indicated (VAI)," Cadila Healthcare said.

This was a product specific pre-approval inspection with general current good manufacturing practice (cGMP) and there were no data integrity related observations, it added.

"The company is confident of addressing these observations and responding to the USFDA at the earliest," Cadila Healthcare said.

As per the USFDA, VAI means that "objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action".

Shares of Cadila Healthcare Monday closed at Rs 253 per scrip on the BSE, up 2.22 per cent from its previous close.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 03 2019 | 4:45 PM IST

Next Story